K

Janus Henderson Investors logo

Janus Henderson Investors

Crunchbase
Pitchbook
Crunchbase

Deals on record

10

Common Fundraising Type

Series B

Heartflow logo
Heartflow

AI technology • Coronary artery disease

US Venture Partners logo
Martis Capital logo
Janus Henderson Investors logo
HealthCor logo

Heartflow, Inc. develops AI technology to improve the diagnosis and management of coronary artery disease through coronary computed tomography angiography.

Debt
$98M
03/27/2025
Article
Curevo logo
Curevo

Biotechnology • Vaccines

Medicxi logo
Sanofi Ventures logo
RA Capital Management logo
OrbiMed logo

Curevo is a biotechnology company focused on developing vaccines with improved tolerability and accessibility, currently advancing a shingles vaccine called amezosvatein.

Series B
$110M
03/17/2025
Article
Bambusa Therapeutics logo
Bambusa Therapeutics

Biotechnology • Inflammatory

RA Capital Management logo
Redmile Group logo
Janus Henderson Investors logo
Invus logo

Bambusa Therapeutics is a biotechnology company developing transformative treatments for inflammatory and immunological conditions.

Series A
$90M
02/18/2025
Article
Angitia Biopharmaceuticals logo
Angitia Biopharmaceuticals

Biotechnology • Clinical-stage

Yonghua Capital logo
OrbiMed logo
Legend Capital logo
Janus Henderson logo

Angitia Biopharmaceuticals is a clinical-stage biotechnology company developing novel treatments for serious musculoskeletal diseases.

Series C
$120M
12/11/2024
Article
nChroma Bio logo
nChroma Bio

Epigenetic editing • Genetic medicines

Wilson Sonsini Goodrich & Rosati logo
Wellington Management logo
T. Rowe Price logo
Sofinnova Partners logo

nChroma Bio develops innovative genetic medicines using epigenetic editing and non-viral delivery technologies to treat chronic hepatitis B and D.

Equity
$75M
12/11/2024
Article
Maze Therapeutics logo
Maze Therapeutics

Biopharmaceutical • Clinical-stage

Frazier Life Sciences logo
Deep Track Capital logo
Logos Capital logo
Janus Henderson Investors logo

Maze Therapeutics is a biopharmaceutical company focused on developing precision medicines for renal and metabolic diseases using human genetics.

Series D
$115M
12/03/2024
Article
Metsera logo
Metsera

Biopharmaceutical • Clinical-stage

Venrock logo
Wellington Management logo
T. Rowe Price logo
SymBiosis logo

Metsera is a clinical-stage biopharmaceutical company developing next-generation treatments for obesity and metabolic diseases using their innovative platforms and Nutrient-Stimulated Hormone analog peptides.

Series B
$215M
11/13/2024
Article
Alpha-9 Oncology logo
Alpha-9 Oncology

Radiopharmaceuticals • Clinical-stage

Ascenta Capital logo
Lightspeed Venture Partners logo
Samsara BioCapital logo
RA Capital Management logo

Alpha-9 Oncology Inc. develops targeted radiopharmaceuticals to improve cancer treatment.

Series C
$175M
10/23/2024
Article
Aktis Oncology logo
Aktis Oncology

Biotechnology • Clinical-stage

RA Capital Management logo
RTW Investments logo
Janus Henderson Investors logo
T. Rowe Price Associates logo

Aktis Oncology is a clinical-stage biotechnology company developing a proprietary radiopharmaceutical pipeline, including Nectin-4-targeted miniprotein radioconjugates, for cancer treatment.

Series B
$175M
09/30/2024
Article
Parse Biosciences logo
Parse Biosciences

Single Cell Sequencing • Life Sciences

Parse Biosciences is a company that develops and commercializes scalable single-cell sequencing technologies for use in over 1,000 labs globally, aiming to expand its product range and market presence with its recent $50 million funding.

Hybrid C
$50M
12/14/2023
Article